Quality & Regulatory Consulting Case Studies
Representative examples of how QA PharmaPro approaches business-critical Quality and Regulatory problems. Client-identifying details are intentionally omitted.
Private-Label Medical Device Regulatory Assessment
Business problem: A company needed to understand whether an existing medical-device pathway and supplier documentation could support a private-label commercialization strategy in the U.S.
QA PharmaPro approach: Review the intended commercial model, predicate and clearance context, labeling implications, manufacturer responsibilities and evidence gaps before recommending the regulatory route.
Value: The client received a decision-oriented assessment before committing additional resources to a pathway that could create downstream regulatory exposure.
Result: Material evidence and responsibility gaps were surfaced before further resources were committed to the U.S. commercialization route.
Related capability: Regulatory strategy and market readiness consulting.
eQMS Readiness for a Regulated SaaS Platform
Business problem: A software platform designed to support regulated Quality processes needed a stronger validation and Quality narrative for customers operating under FDA and EU expectations.
QA PharmaPro approach: Define intended use, risk-based validation expectations, controlled-document and training evidence, electronic-record considerations, supplier responsibilities and a scalable package for regulated customers.
Value: The work translated technical functionality into a more defensible compliance position and a clearer implementation roadmap for enterprise use.
Result: The platform team received a prioritized roadmap connecting intended use, validation expectations, electronic-record controls and customer-facing evidence.
Related capability: GxP software validation, CSA and Part 11 consulting.
Label and Claims Risk Review Before Commercial Launch
Business problem: A consumer-health product required review of label content and marketing claims before launch, with concern around disease implications, substantiation and marketplace exposure.
QA PharmaPro approach: Review mandatory label elements, claim wording, implied disease or treatment positioning, required disclaimers, substantiation risk and high-priority corrections.
Value: The client received a corrected, prioritized view of gaps that could otherwise lead to regulator, marketplace or customer challenges after launch.
Result: High-priority label and claims corrections were identified before launch, reducing avoidable regulatory and marketplace exposure.
Related capability: Product, labeling and marketplace compliance.